Recent Articles

Crizotinib Shows Promise for Childhood Cancers

| September 5, 2017 | 0 Comments

Crizotinib Shows Promise for Childhood Cancers In a small clinical trial, the drug crizotinib shrank tumors in children with cancers that have alterations in the ALK gene. See Original Article

Continue Reading

New on NCI’s Websites for September 2017

| September 1, 2017 | 0 Comments

New on NCI’s Websites for September 2017 NCI periodically provides updates on new websites and other online content of interest to the cancer community.See Original Article

Continue Reading

Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support

| August 31, 2017 | 0 Comments

Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support Researchers recognized the potential of endoxifen as a treatment for breast cancer and, with NCI support, developed the compound into a drug now being tested in clinical trials.See Original Article

Continue Reading

Modified Stem Cells Deliver Chemotherapy to Metastatic Tumors

| August 30, 2017 | 0 Comments

Modified Stem Cells Deliver Chemotherapy to Metastatic Tumors Researchers have used modified stem cells to deliver a cancer drug selectively to metastatic breast cancer tumors in mice. The stem cells target metastatic tumors by homing in on the stiff environment that typically surrounds them.See Original Article

Continue Reading

CRCHD Hosts Career Development and Scientific Workshop

| August 30, 2017 | 0 Comments

CRCHD Hosts Career Development and Scientific Workshop CRCHD recently hosted a Career Development and Scientific Workshop to support investigators interested in applying for Continuing Umbrella of Research Experiences (CURE) and cancer health disparities translational research funding opportunities.See Original Article

Continue Reading

Two New Therapies Approved for Acute Myeloid Leukemia

| August 28, 2017 | 0 Comments

Two New Therapies Approved for Acute Myeloid Leukemia FDA has approved two new treatments for some adult patients with acute myeloid leukemia (AML): enasidenib (Idhifa®), which targets the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos®), a two-drug chemotherapy combination encapsulated in liposomes.See Original Article

Continue Reading

Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis

| August 25, 2017 | 0 Comments

Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis A diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months after beginning treatment, a new study suggests. Within 6 months of a diagnosis, the risk of either event was more than twice that seen in people […]

Continue Reading

Neratinib Approved by FDA for HER2-Positive Breast Cancer

| August 23, 2017 | 0 Comments

Neratinib Approved by FDA for HER2-Positive Breast Cancer FDA has approved neratinib for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab.See Original Article

Continue Reading

NCI Program Supports Small Businesses to Advance Cancer Research Innovation – A Q&A with Michael Weingarten

| August 21, 2017 | 0 Comments

NCI Program Supports Small Businesses to Advance Cancer Research Innovation – A Q&A with Michael Weingarten NCI’s Small Business Innovation Research Program recently issued contract solicitations to spur the development of new cancer-related therapies and technologies, including seven opportunities specific to the Cancer Moonshot.See Original Article

Continue Reading

Ras–dependent Paracrine Cascades

| August 17, 2017 | 0 Comments

Ras–dependent Paracrine Cascades Most pancreatic cancers are driven by mutant K-Ras genes, and comprise a minority of cancer cells in a densely fibrotic and highly secretory tumor microenvironment. Interrupting the paracrine cascades in pancreatic cancers may improve treatment.See Original Article

Continue Reading